Novel therapeutic approaches for phosphate regulation

Area of Science:

• Nephrology
• Pharmacology
• Gastroenterology

Background:

• Hyperphosphatemia in chronic kidney disease (CKD) is linked to vascular calcification and mortality.
• Current phosphate binders present treatment challenges and ongoing debate exists regarding optimal serum phosphate targets.

Purpose of the Study:

• To review recent clinical and experimental studies on phosphate-lowering therapies in CKD.
• To explore novel therapeutic strategies for managing hyperphosphatemia.

Main Methods:

• Review of recent clinical trials and experimental studies on phosphate-lowering agents.
• Analysis of new drug candidates including oxylanthanum carbonate, tenapanor, and AP306.
• Examination of synbiotic therapy's role in modulating gut microbiota and phosphate absorption.

Main Results:

• The HiLo trial, aimed at defining optimal phosphate targets, was terminated early and underpowered.
• New agents like oxylanthanum carbonate (smaller pill size) and tenapanor (inhibits paracellular transport) show promise.
• AP306 (inhibits transcellular transport) demonstrates superior phosphate lowering compared to sevelamer carbonate.
• Gastrointestinal side effects remain a concern with new agents; synbiotic therapy shows potential in animal models.

Conclusions:

• Combining phosphate binders with agents inhibiting intestinal phosphate absorption may enhance hyperphosphatemia treatment and reduce pill burden in CKD.
• Establishing optimal serum phosphate targets and understanding mortality benefits are crucial for minimizing adverse effects.